S. Hanauer

1.1k total citations
36 papers, 859 citations indexed

About

S. Hanauer is a scholar working on Genetics, Epidemiology and Hepatology. According to data from OpenAlex, S. Hanauer has authored 36 papers receiving a total of 859 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 24 papers in Epidemiology and 9 papers in Hepatology. Recurrent topics in S. Hanauer's work include Inflammatory Bowel Disease (26 papers), Microscopic Colitis (22 papers) and Liver Diseases and Immunity (9 papers). S. Hanauer is often cited by papers focused on Inflammatory Bowel Disease (26 papers), Microscopic Colitis (22 papers) and Liver Diseases and Immunity (9 papers). S. Hanauer collaborates with scholars based in United States, Canada and Germany. S. Hanauer's co-authors include Malcolm Robinson, Sanjeev Arora, Walter M. Roufail, Michael Safdi, John P. Cello, Bret A. Lashner, Paul Rutgeerts, Hari S. Conjeevaram, Alfred L. Baker and Helen S. Te and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

S. Hanauer

34 papers receiving 826 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Hanauer United States 14 673 522 246 140 107 36 859
Juris Pokrotnieks Latvia 11 528 0.8× 405 0.8× 195 0.8× 63 0.5× 45 0.4× 26 680
Irene T. Weterman Netherlands 19 724 1.1× 484 0.9× 408 1.7× 156 1.1× 73 0.7× 35 1.0k
J. Chao United States 8 546 0.8× 425 0.8× 198 0.8× 38 0.3× 28 0.3× 46 689
F. Pallone Italy 8 333 0.5× 269 0.5× 173 0.7× 46 0.3× 49 0.5× 15 505
Adrian Goldiș Romania 12 464 0.7× 358 0.7× 191 0.8× 23 0.2× 116 1.1× 35 770
Cloé Charpentier France 12 502 0.7× 366 0.7× 271 1.1× 40 0.3× 54 0.5× 38 687
Michael D. deB. Edwardes Canada 7 333 0.5× 305 0.6× 190 0.8× 29 0.2× 68 0.6× 16 560
Sawan Bopanna India 19 465 0.7× 307 0.6× 471 1.9× 41 0.3× 108 1.0× 44 953
Ann Corken Mackey United States 5 247 0.4× 219 0.4× 86 0.3× 86 0.6× 54 0.5× 5 514
Paula Lago Portugal 18 540 0.8× 380 0.7× 222 0.9× 59 0.4× 66 0.6× 62 934

Countries citing papers authored by S. Hanauer

Since Specialization
Citations

This map shows the geographic impact of S. Hanauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Hanauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Hanauer more than expected).

Fields of papers citing papers by S. Hanauer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Hanauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Hanauer. The network helps show where S. Hanauer may publish in the future.

Co-authorship network of co-authors of S. Hanauer

This figure shows the co-authorship network connecting the top 25 collaborators of S. Hanauer. A scholar is included among the top collaborators of S. Hanauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Hanauer. S. Hanauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schreiber, S, et al.. (2025). P0834 Mucosal improvement and histologic healing with amiselimod for active Ulcerative Colitis: a phase 2, randomised, placebo-controlled trial. Journal of Crohn s and Colitis. 19(Supplement_1). i1592–i1593. 2 indexed citations
2.
3.
Hanauer, S., Stefan Schreiber, Ole Østergaard Thomsen, et al.. (2008). P005 ANALYSIS OF PREDICTORS OF RESPONSE MAINTENANCE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE CROHN'S DISEASE: DATA FROM PRECISE 2. 2(1). 6–6. 2 indexed citations
4.
Hanauer, S.. (2006). New lessons: classic treatments, expanding options in ulcerative colitis. Colorectal Disease. 8(s1). 20–24. 13 indexed citations
5.
Hanauer, S.. (2006). Review article: high‐dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Alimentary Pharmacology & Therapeutics. 24(s3). 37–40. 43 indexed citations
6.
Sandborn, William J., S. Hanauer, Douglas C. Wolf, et al.. (2005). Maintenance of Remission over 1 Year in Patients with Active Crohnʼs Disease Treated with Adalimumab. The American Journal of Gastroenterology. 100. S311–S311. 11 indexed citations
7.
Feagan, Brian G., William J. Sandborn, J. P. Baker, et al.. (2005). A randomized, double‐blind, placebo‐controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, in patients with corticosteroid‐dependent Crohn's disease. Alimentary Pharmacology & Therapeutics. 21(4). 373–384. 26 indexed citations
8.
Sandborn, WJ, Walter Reinisch, D Rachmilewitz, et al.. (2005). Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial. Zeitschrift für Gastroenterologie. 43(5). 39 indexed citations
9.
Sandborn, William J., S. Hanauer, & Akshay Buch. (2004). Comparative pharmacokinetics of equimolar doses of 5‐aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single‐dose, crossover study in healthy volunteers1. Alimentary Pharmacology & Therapeutics. 19(10). 1089–1098. 25 indexed citations
10.
Te, Helen S., et al.. (2000). Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. The American Journal of Gastroenterology. 95(11). 3150–3156. 106 indexed citations
11.
D’Haens, G., Isolde Aerden, John B. Kisiel, et al.. (1999). Duration of response following cessation of infliximab therapy for active or fistulizing Crohn's disease. Gastroenterology. 116(4). 15 indexed citations
12.
Hanauer, S.. (1999). Safety of infliximab in clinical trials. 13(4). 16–22. 22 indexed citations
13.
Hanauer, S., et al.. (1998). The effect of gender on quality of life (QOL) instruments in IBD. Gastroenterology. 114. A919–A919. 2 indexed citations
14.
Hanauer, S., et al.. (1998). Methotrexate in Crohn's disease: How is it doing?. Gastroenterology. 114. A951–A951. 7 indexed citations
15.
Sutherland, L R, S. Hanauer, & Jürgen Schölmerich. (1997). Standards for trials of therapy in inflammatory bowel disease. Inflammatory Bowel Diseases. 3(4). 277–283. 4 indexed citations
16.
Sutherland, L R, S. Hanauer, & Jürgen Schölmerich. (1997). Standards for Trials of Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 3(4). 277–283. 2 indexed citations
17.
Hanauer, S., et al.. (1997). Leukotrienes in ulcerative colitis: Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology. 112(3). 725–732. 61 indexed citations
18.
Bank, S, Charles A. Sninsky, Max Robinson, et al.. (1997). SAFETY AND ACTIVITY EVALUATION OF rhlL-11 IN SUBJECTS WITH ACTIVE CROHNʼS DISEASE.. Shock. 7(Supplement). 131–131. 4 indexed citations
19.
Robinson, Malcolm, et al.. (1994). Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics. 8(1). 27–34. 28 indexed citations
20.
Lashner, Bret A., et al.. (1990). Colon cancer surveillance in chronic ulcerative colitis: historical cohort study.. PubMed. 85(9). 1083–7. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juris Pokrotnieks Breakdown of academic impact, for papers by Irene T. Weterman Breakdown of academic impact, for papers by J. Chao Breakdown of academic impact, for papers by F. Pallone Breakdown of academic impact, for papers by Adrian Goldiș Breakdown of academic impact, for papers by Cloé Charpentier Breakdown of academic impact, for papers by Michael D. deB. Edwardes Breakdown of academic impact, for papers by Sawan Bopanna Breakdown of academic impact, for papers by Ann Corken Mackey Breakdown of academic impact, for papers by Paula Lago
Rankless by CCL
2026